Louis ED. Treatment of essential tremor: are there issues we are looking for? Front Neurol 2012;2:1-8. doi: 10.3389/fneur.2011.00091.

Louis ED. Age of onset: can we rely on essential tremor patients to report this? Data from a prospective, longitudinal study. Neuroepidemiology 2013;40:93-8. DOI: 10.1159/000341903.

Louis ED, Gerbin M, Galecki M. Essential tremor 10, 20, 30, 40: clinical snapshots of the disease by decade of duration. Eur J Neurol 2013; 20: 949-54. DOI: 10.1111/ene.12123.

Prasad S, Bhalsing KS, Hunjhunwala K, Lenka A, Binu VS, Pal PK. Phenotypic variability of essential tremor based on the age at onset. Canadian J Neurol Sci 2019; 46: 192-8. DOI: 10.1017/cjn.2018.384.

Taylor GS. Essential tremor: a review. 2021. Honors Projects. 814.

Jiménez‐Jiménez F, Alonso-Navarro H, García-Martín E, Lorenzo-Betancor O, Pastor P, Agúndez JAG. Update on genetics of essential tremor. Acta Neurol Scand 2013;128:359-71. DOI: 10.1111/ane.12148.

Louis ED, McCreary M. How common is essential tremor? Update on the worldwide prevalence of essential tremor. Tremor Other Hyperkinetic Movements 2021;11:28. DOI: 10.5334/tohm.632.

Kuhlenbäumer GF , Hopfner F, Deuschl G. Genetics of essential tremor: meta-analysis and review. Neurology 2014;82:1000-7. DOI: 10.1212/WNL.0000000000000211.

Louis ED, Babij R, Ma K, Cortés E, Vonsattel JPG. Essential tremor followed by progressive supranuclear palsy: postmortem reports of 11 patients. J Neuropathol Exp Neurol 2013;72:8-17. DOI: 10.1097/NEN.0b013e31827ae56e.

Kandemir N, Gultekin M, Kara M, et al. Propranolol decreases DRD3 and SLC1A2 gene expression in patients with essential tremor. Univ Med 2020;39:105-12. doi: 10.18051/UnivMed.2020.v39.10.

Tio M, Tan EK. Genetics of essential tremor. Parkinsonism Relat Disord 2016;22 Suppl 1:S176-S8.DOI: 10.1016/j.parkreldis.2015.09.022.

Ondo WG. Current and emerging treatments of essential tremor. Neurol Clin 2020;38:309-23. DOI: 10.1016/j.ncl.2020.01.002.

Morales J, Li L, Fattah FJ, et al. Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit Rev Eukaryot Gene Expr 2014;24:15-28. DOI: 10.1615/critreveukaryotgeneexpr.2013006875.

Swindall AF, Stanley JA, Yang ES. PARP-1: friend or foe of DNA damage and repair in tumorigenesis? Cancers 2013;5:943-58. doi: 10.3390/cancers503094.3

Hoch NC, Polo LM. ADP-ribosylation: from molecular mechanisms to human disease. Genet Mol Biol 2020;43(1 Suppl 1):e20190075. DOI: 10.1590/1678-4685-GMB-2019-0075.

Zhou T, Pan F, Cao Y, et al. R152C DNA Pol β mutation impairs base excision repair and induces cellular transformation. Oncotarget 2016;7:6902–15. DOI: 10.18632/oncotarget.6849.

Fahn S, Tolosa E, Marín C. Clinical rating scale for tremor. In: Jankovic J, Tolosa E, editors. Parkinson’s disease and movement disorders. 2nd. ed. Baltimore: Williams & Wilkins; 1993. p. 225-3.

Cersonsky TEK, Kellner S, Morganet S, et al. Demoralization in essential tremor: prevalence, clinical correlates, and dissociation from tremor severity. CNS Spectr 2020 ;25:16-23.. DOI: 10.1017/S1092852918001633.

Alonso-Navarro H, García-Martín E, Agúndez JAG, Jiménez-Jiménez FJ. Association between restless legs syndrome and other movement disorders. Neurology 2019;92:948-64. DOI: 10.1212/WNL.0000000000007500.

Diez-Fairen M, Bandres-Ciga S, Houle G, et al. Genome-wide estimates of heritability and genetic correlations in essential tremor. Parkinsonism Relat Disord 2019;64:262-7. DOI: 10.1016/j.parkreldis.2019.05.002.

Hopfner F, Helmich RC. The etiology of essential tremor: genes versus environent. Parkinsonism Relat Disord 2018;46 Suppl 1:S92-S6. doi: 10.1016/j.parkreldis.2017.07.014.

Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E. Álvarez I, Pastor P, Agúndez JAG. Genomic markers for essential tremor. Pharmaceuticals 2021;14:516. https://doi.org/10.3390/ph14060516J.

Liao C, Sarayloo F, Rochefort D, et al. Multiomics analyses identify genes and pathways relevant to essential tremor. Mov Disord 2020;35:1153-62. doi: 10.1002/mds.28031.

Shanker V. Essential tremor: diagnosis and management. BMJ 2019;366:l4485. doi: 10.1136/bmj.l4485.

Hopfner F, Höglinger GU, Kuhlenbäumer G, et al. β-adrenoreceptors and the risk of Parkinson's disease. Lancet Neurology 2020;19:247-54. DOI: 10.1016/S1474-4422(19)30400-4.

Fatokun AA, Dawson VL, Dawson TM. Parthanatos: mitochondrial‐linked mechanisms and therapeutic opportunities. Br J Pharmacol 2014;71:2000-16. doi: 10.1111/bph.12416.

Maynard S, Fang EF, Scheibye-Knudsen M, Croteau DL, Bohr VA. DNA damage, DNA repair, aging, and neurodegeneration. Cold Spring Harb Perspect Med 2015;18:a025130. doi: 10.1101/cshperspect.a025130.

Fang EF, Scheibye-Knudsen M, Brace LE, et al. Defective mitophagy in XPA via PARP-1 hyperactivation and NAD(+)/SIRT1 reduction. Cell 2014;157:882-96. doi: 10.1016/j.cell.2014.03.026.

Anandhan A, Jacome MS, Lei S, et al. Metabolic dysfunction in Parkinson's disease: bioenergetics, redox homeostasis and central carbon etabolism. Brain Res Bull 2017;133:12-30. doi: 10.1016/j.brainresbull.2017.03.009.

Brighina L, Rivab C Bertola F,et al. Association analysis of PARP1 polymorphisms with Parkinson’s disease. Parkinsonism Rel Disord 2011;17:701-4. https://doi.org/ 10.1016/j.parkreldis.2011.06.022.

Alemasova EE, Lavrik OI. Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins. Nucleic Acids Res 2019;47:3811-27. doi: 10.1093/nar/gkz120.

Adamczyk A, Kaźmierczak A, Czapski GA, Strosznajder JB. Alpha-synuclein induced cell death in mouse hippocampal (HT22) cells is mediated by nitric oxide-dependent activation of caspase-3. FEBS Lett 2010;584:3504-8. doi: 10.1016/j.febslet.2010.07.019.

Kamal SJ, Khadhim HM. Effects of Irbesartan in induced Parkinson’s disease in mice. Int J Pharmaceut Qual Assur 2021;12:31-9. DOI: 10.25258/ijpqa.12.1.5.

Renani PG, Taheri F, Rostami D, et al. Involvement of aberrant regulation of epigenetic mechanisms in the pathogenesis of Parkinson's disease and epigenetic-based therapies. J Cell Physiol 2019;234:19307-19. doi: 10.1002/jcp.28622.

Broniowska KA, Diers AR, Corbett JA, Hogg N. Effect of nitric oxide on naphthoquinone toxicity in endothelial cells: role of bioenergetic dysfunction and poly (ADP-ribose) polymerase activation. Biochemistry 2013;52:4364-72. doi: 10.1021/bi400342t.

Maciag AE, Holland RJ, Kim Y, et al. Nitric oxide (NO) releasing poly ADP-ribose polymerase 1 (PARP-1) inhibitors targeted to glutathione S-transferase P1-overexpressing cancer cells. J Med Chem 2014;57:2292-302. doi: 10.1021/jm401550d.

Krokan HE, Bjøras M. Base excision repair. Cold Spring Harb Perspect Biol 2013;5:a012583. doi: 10.1101/cshperspect.a012583.

Beard WA, Wilson SH. DNA polymerase beta and other gap-filling enzymes in mammalian base excision repair. Enzymes 2019;45:1-26. doi: 10.1016/bs.enz.2019.08.002.

Wang H, Chen Y, Chen J, Cell cycle regulation of DNA polymerase beta in rotenone-based Parkinson's disease models. PLoS One 2014;9:e109697. doi: 10.1371/journal.pone.0109697.